An increasing proportion of new cancers is registered in patients who have received a previous cancer diagnosis. As data are inconsistent across studies, we provided information for populations long covered by valid cancer registration. Data were derived from the Swiss cancer Registries of Vaud and Neuchâtel (885 000 inhabitants). Patients diagnosed with a new malignancy (except skin basal and squamous cell carcinomas) during the period 2005-2010 were included. Over the period 2005-2010, 24 859 patients were registered with incident cancer. Of these, 3127 (13%) had multiple primary cancers and 578 (2.3%) were synchronous. Breast, prostate, colorectum, skin, melanomas, and squamous cell carcinomas of the head and neck (SHN) and bladder/ureter were the most common sites of first neoplasms, whereas breast, lung, colorectum, prostate, melanoma, and SHN were the most common sites of second neoplasms. The most common pairing was breast with breast (31% synchronous), followed by the bladder/ureter with the prostate (72% synchronous), prostate with the colorectum, SHN with SHN, and SHN with lung. Five-year crude survival of patients with synchronous cancers (34%) was not significantly lower than that of patients with single neoplasms (39%). This populationbased study indicates that about one in eight incident neoplasms in these mature registries are second neoplasms and almost 1/40 patients are diagnosed with synchronous primary cancers. These are related to shared genetic and environmental factors as well as diagnostic and therapeutic procedures. As cancer diagnosis and survival is likely to improve, the proportion of patients with multiple primary cancers will further increase in the future. 
Introduction
The combined effect of improved cancer diagnosis and management has led to a marked increase in cancer survivors. Consequently, an appreciable proportion of cancers are registered among patients who had already received a cancer diagnosis in the past, and more sophisticated and accurate diagnostic procedures lead to the identification of more than one cancer in a subset of patients.
However, there are relatively few population-based data sets on second primary cancers. In the SEER dataset (Travis, 2006) , about one in six (16%) incident cancers were in patients with multiple primary cancers, and some of these were related to radiotherapy or other types of therapy. The proportion of multiple primary cancers was much smaller (1%) in a Turkish hospital-based series (Aydiner et al., 2000) , but was 11.4% in the Minneapolis Veteran Affairs tumor registry (Powell et al., 2013) , which, however, included over 90% men, nonrepresentative of the baseline sociodemographic characteristics and of the age distribution of the general population. The proportion of second primary cancers was also lower (3.8%) in a Portuguese study, from the North Region Cancer Registry, over the period -2003 (Pacheco-Figueiredo et al., 2013 . Of these, 78% were metachronous. It was 6.3% in the EUROCARE-4 study, including 57 European registries, but with marked variations (from 0.4% in Naples to 12.9% in Ireland, Rosso et al., 2009) . These varying proportions, in fact, are a function of baseline incidence, diagnostic accuracy, and mainly the sex and the age of the various cohorts considered.
To provide additional, population-based information on the issue, we considered multiple primary neoplasms registered in the cancer Registries of the Swiss cantons of Vaud and Neuchâtel over the period 2005-2010. 
Materials and methods
Our study used data derived from the Vaud and Neuchâtel cancer Registries' datasets, which include information on incident cases of malignant neoplasms occurring in the two Swiss cantons (respectively, about 713 000 and 172 000 inhabitants, according to the December 2010 National Census) (Levi et al., 2007a (Levi et al., , 2007b (Waterhouse et al., 1982) .
In both cantons, population-based incidence data have been available since 1974. The main information comprises the demographic characteristics of the patient, primary site, and histological type of the tumor according to the standard international classification of Diseases for Oncology (ICD-O-1 and both ICD-O-1 and ICD-O-3 since 2005) (World Health Organization, 1976 .
Passive and active follow-up was recorded, and each subsequent item of information on already registered cases was used to complete the record of that patient. Information from the death certificate was added to the registration file.
After exclusion of basal and squamous cell carcinomas of the skin from the entire database (calendar period 1974-2010) , patients diagnosed with a new primary malignancy, either first or second primary, during the calendar period 2005-2010 were abstracted from the Registries' databases. All second neoplasms were categorized as synchronous (i.e. classified as those diagnosed within 6 months or less) or metachronous. Anatomical site as well as morphological type were usedwhen indicated -to categorize primary or groups of primary sites. In particular, malignant melanomas and other non basal-cell and non squamous cell carcinomas of the skin were grouped together as 'Melanomas and other skin' (MOS), whereas squamous cell carcinomas of the oral cavity, pharynx, hypopharynx, and larynx were grouped together as 'Squamous head and neck' (SHN), esophageal and gastric sites were grouped together as 'Gastroesophageal', pancreas and biliary tract were grouped together as 'Pancreatobiliary', and bladder and ureter were grouped together as 'Bladder/ ureter'.
Absolute and relative frequencies, and medians are presented to describe the main characteristics of patients, tumors, and pairings of tumors.
Survival curves were defined according to the product-limit (maximum likelihood) method (Kaplan and Meier, 1958) for patients with synchronous cancers versus those with only a single malignancy. Differences in survival were tested using the log-rank method.
Results
A total of 24 859 patients (13 132 men and 11 727 women) were registered with incident cancer in the Vaud and Neuchâtel cancer Registries over the period [2005] [2006] [2007] [2008] [2009] [2010] . Of these, 3127 (13%; 1712 men and 1415 women) had multiple primary cancers. In about 2/3 of these (n = 2026), the first primary was diagnosed before 2005. The median age at diagnosis was 64.0 years for first metachronous and 73.2 years for second metachronous primaries, and 69.0 years for synchronous neoplasms. Table 1 presents the ranks for the most common sites of first (breast, prostate, colorectum, MOS, SHN, and bladder/ureter) and second neoplasms (breast, lung, colorectum, prostate, MOS, and SHN). In 18% of pairs (578/3127; 348 men and 230 women), primaries were synchronous. Table 2 presents the most common malignancy pairings for synchronous and metachronous cancers combined, and for synchronous cancers only. The most common pairing was breast with breast, in 236 patients. Of these, about a third (73) were synchronous. The second pairing was the bladder/ureter with the prostate, in 98 patients. Of these, 71 (about 3/4) were synchronous. These were followed by prostate with colorectum (87 patients, five synchronous) and by SHN with SHN (74 patients, 19 synchronous), and SHN with lung (73 patients, 15 synchronous). 
Discussion
This population-based study, covering all registered incident neoplasms in two Swiss cantons, indicates that about one in eight incident neoplasms are second primary and almost 1/40 patients are diagnosed with synchronous primary cancers. For some neoplasms, including breast, prostate, MOS, and colorectum, this reflects the high prevalence of long-term survivors, but in some cases, this may also reflect an increased risk of specific cancers because of shared genetic factors (i.e. breast with colorectum, corpus uteri, and ovary) and a high frequency of synchronous cancers (Ford et al., 1994; Breast Cancer Linkage Consortium, 1999; Lynch and de la Chapelle, 2003; Travis, 2006; Vogel, 2006; Levi et al., 2008a; Turati et al., 2013) . Shared exposure to environmental factors, perhaps together with genetic factors (Garavello et al., 2005; Travis et al., 2006) , may also explain the frequent occurrence of selected combinations of cancers, including tobacco and alcohol for head and neck (Pelucchi et al., 2008) , and tobacco for head and neck and lung, and bladder and lung (Levi et al., 1999; Gandini et al., 2008) . Some pairings are affected by diagnostic procedures following the diagnosis of a first primary. These include breast with breast and colorectum with colorectum (Levi et al., 2013) , but this is particularly evident for selected pairings of synchronous cancers. Thus, the frequent identification of a prostate cancer in patients with bladder or other urinary tract cancers, most of which were synchronous, is because of diagnostic ascertainment and the high frequency of foci of prostate cancer in elderly men (Montie et al., 1989; Abbas et al., 1996; Levi et al., 2008b; Fontes et al., 2013) .
Other pairings are also influenced by the therapy for the first cancer (Travis, 2002) . Thus, radiotherapy may at least in part explain the frequent occurrence of (colo) rectal and of bladder cancer following prostate cancer or of lung cancer following breast cancer (Preston et al., 2002; Boice, 2006; Travis, 2006) . Of interest, in any case, is the relatively small number of leukemias, that is the type of neoplasm showing the highest excess risk in the short term (Kaldor et al., 1990; Preston et al., 2002; Boice, 2006; Levi et al., 2006) .
Second cancer pairings are in broad agreement with those of the Utah Population Data Base, which found associations between breast, ovary, rectum, and thyroid; between prostate, bladder, brain, leukemia, and lymphoma; between colon, stomach, prostate, and rectum; and between bladder, lung, lip, larynx, and cervix (Teerlink et al., 2012) .
A major advantage of these Swiss datasets is that, in the populations considered, there is a long tradition of accurate and valid cancer registration, as well as of systematic examination of all surgically treated lesions, including skin melanomas (Levi et al., 2008b) . This may explain the appreciably higher proportion of second primary cancers in these datasets compared with other European registrybased series (Rosso et al., 2009; Pacheco-Figueiredo et al., 2013) , together with the longer time of functioning of our registries.
There was no significant difference in survival between patients with synchronous neoplasms and those with single ones. This is in line with the findings of the EUROCARE-4 study, which found only a modest difference (about 0.5%) in 5-year survival between patients with single and those with multiple tumors (Rosso et al., 2009) . No comparison is possible with patients with metachronous cancers as the diagnosis of a second neoplasm is a function of longer survival. In fact, 5-year crude survival of patients with metachronous neoplasms was 0.87.
As cancer diagnosis and survival will further improve in the foreseeable future, some of the aspects mentioned above are likely to increase in importance, together with a probable further increase in the proportion of patients with multiple primary cancers. 
